Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

438
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
438
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

266
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
266
Hypersensitivity Reactions: Cytolytic Reactions01:01

Hypersensitivity Reactions: Cytolytic Reactions

69
Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
69
Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

292
Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
292
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

554
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
554
Hemodialysis I: Introduction01:25

Hemodialysis I: Introduction

2.3K
Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
2.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to "Identifying distinct clinical phenotypes and outcomes in adult-onset IgA vasculitis using unsupervised clustering analysis" [European Journal of Internal Medicine 147 (2026) 106742].

European journal of internal medicine·2026
Same author

Dialysis disequilibrium syndrome: an underdiagnosed condition? Results from a monocentric observational study.

Clinical kidney journal·2026
Same author

Kidney biopsy during pregnancy: indications, complications, results and therapeutic impact.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026
Same author

Infectious complications of ANCA-associated vasculitis: Description and associated outcome.

European journal of internal medicine·2026
Same author

Belimumab use in paediatric-onset systemic lupus erythematosus: a status report in France from a retrospective multicentre descriptive study.

Rheumatology (Oxford, England)·2026
Same author

Challenges of ongoing VKA use in calciphylaxis: The potential of multimodal treatment including rheopheresis, — a case report

Nephrologie & therapeutique·2026

Related Experiment Video

Updated: Feb 28, 2026

Supervised Machine Learning for Semi-Quantification of Extracellular DNA in Glomerulonephritis
09:16

Supervised Machine Learning for Semi-Quantification of Extracellular DNA in Glomerulonephritis

Published on: June 18, 2020

7.4K

Apheresis to treat systemic vasculitis.

Julie Moussi-Frances1, Marion Sallée2, Noémie Jourde-Chiche2

  • 1Centre de néphrologie et transplantation rénale, hôpital de la Conception, AP-HM, 147, boulevard Baille, 13005 Marseille, France.

Joint Bone Spine
|June 13, 2017
PubMed
Summary

Apheresis, including plasmapheresis and immunoadsorption, removes harmful plasma components for severe vasculitis. Current evidence does not prove one apheresis technique is superior for treating ANCA-associated vasculitis or Goodpasture syndrome.

Keywords:
ANCAAnti-GBMApheresisCryoglobulinemiaImmunoadsorptionPlasma exchangeVasculitis

More Related Videos

Re-Arterialized Rat Partial Liver Transplantation with an in vivo Vessel-Oriented 70% Hepatectomy
14:52

Re-Arterialized Rat Partial Liver Transplantation with an in vivo Vessel-Oriented 70% Hepatectomy

Published on: April 8, 2018

12.4K
An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.7K

Related Experiment Videos

Last Updated: Feb 28, 2026

Supervised Machine Learning for Semi-Quantification of Extracellular DNA in Glomerulonephritis
09:16

Supervised Machine Learning for Semi-Quantification of Extracellular DNA in Glomerulonephritis

Published on: June 18, 2020

7.4K
Re-Arterialized Rat Partial Liver Transplantation with an in vivo Vessel-Oriented 70% Hepatectomy
14:52

Re-Arterialized Rat Partial Liver Transplantation with an in vivo Vessel-Oriented 70% Hepatectomy

Published on: April 8, 2018

12.4K
An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.7K

Area of Science:

  • Nephrology
  • Rheumatology
  • Immunology

Background:

  • Apheresis has been a treatment for severe systemic vasculitides for over 40 years.
  • It aims to rapidly remove autoantibodies or circulating immune complexes from plasma.
  • Key indications include Antineutrophil Cytoplasmic Antibodies (ANCA)-associated vasculitis with severe renal or pulmonary involvement and antiglomerular basement membrane disease (Goodpasture syndrome).

Purpose of the Study:

  • To review the use of apheresis in treating severe systemic vasculitides.
  • To discuss the main apheresis techniques: plasmapheresis and immunoadsorption.
  • To compare the advantages and drawbacks of each technique for current indications.

Main Methods:

  • Review of apheresis techniques used in systemic vasculitis treatment.
  • Discussion of plasmapheresis (filtration, centrifugation, double filtration) and immunoadsorption.
  • Consideration of clinical indications and ongoing trials like PEXIVAS.

Main Results:

  • Apheresis is established for severe vasculitis, targeting autoantibodies and immune complexes.
  • Plasmapheresis and immunoadsorption are the primary techniques employed.
  • The PEXIVAS trial is evaluating plasmapheresis for ANCA-associated vasculitis.

Conclusions:

  • Apheresis remains a vital adjunctive therapy for severe systemic vasculitides.
  • The superiority of plasmapheresis versus immunoadsorption for current indications is not yet established.
  • Further research and trials are necessary to define optimal apheresis strategies.